1. Home
  2. SPHL vs ONCO Comparison

SPHL vs ONCO Comparison

Compare SPHL & ONCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Springview Holdings Ltd Class A Ordinary Shares

SPHL

Springview Holdings Ltd Class A Ordinary Shares

HOLD

Current Price

$2.35

Market Cap

3.9M

ML Signal

HOLD

Logo Onconetix Inc.

ONCO

Onconetix Inc.

HOLD

Current Price

$1.43

Market Cap

4.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SPHL
ONCO
Founded
2002
2018
Country
Singapore
United States
Employees
71
N/A
Industry
Homebuilding
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.9M
4.3M
IPO Year
2024
2022

Fundamental Metrics

Financial Performance
Metric
SPHL
ONCO
Price
$2.35
$1.43
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
144.8K
53.7K
Earning Date
12-29-2025
11-13-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$5,956,226.00
$1,223,751.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.31
$1.42
52 Week High
$62.40
$179.35

Technical Indicators

Market Signals
Indicator
SPHL
ONCO
Relative Strength Index (RSI) 50.02 27.29
Support Level $2.31 $1.54
Resistance Level $3.20 $1.66
Average True Range (ATR) 0.58 0.25
MACD -0.21 -0.08
Stochastic Oscillator 3.72 3.05

Price Performance

Historical Comparison
SPHL
ONCO

About SPHL Springview Holdings Ltd Class A Ordinary Shares

Springview Holdings Ltd is a company that conducts its operations through its indirect wholly-owned subsidiary which designs and constructs residential and commercial buildings in Singapore. It also provides four main types of works which includes new construction, reconstruction, Additions and Alterations (A&A), and other general contracting services such as renovation and design consultation. The company operates and manages its business as a single segment - in the development of construction projects. It derives maximum revenue from its Residential Customers.

About ONCO Onconetix Inc.

Onconetix Inc is a commercial-stage biotechnology company focused on the research, development, and commercialization of solutions for men's health and oncology. It has a product named Entadfi an FDA-approved once-daily oral therapeutic for the treatment of benign prostatic hyperplasia, a disorder of the prostate, along with building additional assets in therapeutics, diagnostics, and clinician services for oncology.

Share on Social Networks: